[Can the precautionary principle obstruct therapeutic progress?].
de Prost
Y
Y
D003876:Dermatitis, Atopic / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D011356:Product Labeling; D018570:Risk Assessment; D016559:Tacrolimus / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D007166:Immunosuppressive Agents; D016559:Tacrolimus